Published in Acta Neuropathol on June 20, 2010
Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease | NCT02605161
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain (2015) 2.32
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.91
Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med (2011) 1.71
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology (2012) 1.69
Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain (2015) 1.51
Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med (2012) 1.41
Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol (2013) 1.34
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26
The role of microglia in synaptic stripping and synaptic degeneration: a revised perspective. ASN Neuro (2010) 1.26
Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis (2012) 1.25
Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles? Acta Neuropathol (2014) 1.24
Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol (2012) 1.14
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther (2013) 1.06
Combining comparative proteomics and molecular genetics uncovers regulators of synaptic and axonal stability and degeneration in vivo. PLoS Genet (2012) 1.04
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain (2014) 1.03
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol (2014) 1.01
IQGAP1 regulates NR2A signaling, spine density, and cognitive processes. J Neurosci (2011) 0.98
The role of DNA repair in brain related disease pathology. DNA Repair (Amst) (2013) 0.96
α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem (2011) 0.96
Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet (2014) 0.95
Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis (2011) 0.95
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci (2012) 0.94
Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice. Hum Mol Genet (2014) 0.94
Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. J Parkinsons Dis (2011) 0.93
Neural stem cells: mechanisms and modeling. Protein Cell (2012) 0.91
Carbon nanotubes and graphene as emerging candidates in neuroregeneration and neurodrug delivery. Int J Nanomedicine (2015) 0.91
The role of glia in α-synucleinopathies. Mol Neurobiol (2012) 0.89
The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther (2014) 0.88
JNK isoforms differentially regulate neurite growth and regeneration in dopaminergic neurons in vitro. J Mol Neurosci (2011) 0.88
Synapses and dendritic spines as pathogenic targets in Alzheimer's disease. Neural Plast (2012) 0.88
Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. Int J Alzheimers Dis (2011) 0.87
Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? Parkinsons Dis (2015) 0.86
Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease? Biomolecules (2015) 0.86
Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity. Dis Model Mech (2014) 0.86
Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. PLoS One (2013) 0.85
Cerebral magnetic resonance elastography in supranuclear palsy and idiopathic Parkinson's disease. Neuroimage Clin (2013) 0.85
Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) (2015) 0.85
Meeting at the crossroads: common mechanisms in Fragile X and Down syndrome. Trends Neurosci (2013) 0.85
Striatal blood-brain barrier permeability in Parkinson's disease. J Cereb Blood Flow Metab (2015) 0.84
Controlled cortical impact results in an extensive loss of dendritic spines that is not mediated by injury-induced amyloid-beta accumulation. J Neurotrauma (2013) 0.84
Neurodegenerative changes initiated by presynaptic dysfunction. Transl Neurodegener (2013) 0.84
Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci (2016) 0.84
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol Dis (2013) 0.83
Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction. RNA Biol (2013) 0.83
Circadian Rhythms, Sleep, and Disorders of Aging. Trends Endocrinol Metab (2016) 0.83
Parkinson's disease. Subcell Biochem (2012) 0.82
A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics (2014) 0.82
Synthesis and in vitro evaluation of α-synuclein ligands. Bioorg Med Chem (2012) 0.82
Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther (2014) 0.82
Adult neurogenesis and neurodegenerative diseases: A systems biology perspective. Am J Med Genet B Neuropsychiatr Genet (2016) 0.81
Involvement of ubiquilin-1 transcript variants in protein degradation and accumulation. Commun Integr Biol (2011) 0.80
Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease. Eur Radiol (2015) 0.79
Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer's disease. Neurobiol Aging (2015) 0.79
Plasma membrane invaginations containing clusters of full-length PrPSc are an early form of prion-associated neuropathology in vivo. Neurobiol Aging (2013) 0.79
Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies. Parkinsonism Relat Disord (2014) 0.79
The ubiquitin-proteasome system and microvascular complications of diabetes. J Ophthalmic Vis Res (2013) 0.79
The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. Mov Disord (2012) 0.78
Mild cognitive impairment in Parkinson's disease: a review of current concepts. Neurol Res Int (2013) 0.78
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. J Neural Transm (Vienna) (2012) 0.78
Contribution of yeast models to neurodegeneration research. J Biomed Biotechnol (2012) 0.78
Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases? Front Psychiatry (2015) 0.77
Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences. Int J Geriatr Psychiatry (2015) 0.77
Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity. Neural Plast (2014) 0.77
Cognitive decline in Parkinson disease. Nat Rev Neurol (2017) 0.77
Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease. Acta Neuropathol Commun (2016) 0.76
Benzothiazole Amphiphiles Promote the Formation of Dendritic Spines in Primary Hippocampal Neurons. J Biol Chem (2016) 0.76
Magnetic resonance spectroscopy in the diagnosis of dementia with Lewy bodies. Biomed Res Int (2014) 0.76
Progressive Axonal Degeneration of Nigrostriatal Dopaminergic Neurons in Calcium-Independent Phospholipase A2β Knockout Mice. PLoS One (2016) 0.75
Aging of perennial cells and organ parts according to the programmed aging paradigm. Age (Dordr) (2016) 0.75
Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP. Front Behav Neurosci (2015) 0.75
Regional functional synchronizations in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr (2016) 0.75
Downregulation of neuronal vasoactive intestinal polypeptide in Parkinson's disease and chronic constipation. Neurogastroenterol Motil (2016) 0.75
Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014. Parkinsons Dis (2016) 0.75
A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. PLoS One (2016) 0.75
The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy. Neural Plast (2017) 0.75
Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats. Neuropsychiatr Dis Treat (2015) 0.75
Changes in functional organization and white matter integrity in the connectome in Parkinson's disease. Neuroimage Clin (2016) 0.75
The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review. Funct Neurol (2016) 0.75
Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. Front Neurol (2017) 0.75
Age- and brain region-dependent α-synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating α-synuclein phosphorylation in aging monkey brains. Oncotarget (2016) 0.75
Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. Neuroimage Clin (2017) 0.75
Integrated analysis of genetic, behavioral, and biochemical data implicates neural stem cell-induced changes in immunity, neurotransmission and mitochondrial function in Dementia with Lewy Body mice. Acta Neuropathol Commun (2017) 0.75
Associated and predictive factors of depressive symptoms in patients with Parkinson's disease. J Neurol (2016) 0.75
Potential Role of Epigenetic Mechanism in Manganese Induced Neurotoxicity. Biomed Res Int (2016) 0.75
Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology. J Neurosci (2016) 0.75
Alpha-synuclein oligomers: a new hope. Acta Neuropathol (2017) 0.75
Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. F1000Res (2017) 0.75
Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell Mol Life Sci (2017) 0.75
α-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci (2017) 0.75
The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease. Front Neurosci (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Diagnostic criteria for Parkinson disease. Arch Neurol (1999) 11.65
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature (2002) 10.81
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol (1983) 7.55
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry (2008) 7.20
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu Rev Neurosci (2001) 6.36
Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell (2005) 6.31
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci (2006) 4.98
The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron (1995) 4.78
Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol (1996) 4.54
Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci (1988) 4.36
Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci (2002) 4.01
Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1993) 3.73
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry (2000) 3.62
Identification of two distinct synucleins from human brain. FEBS Lett (1994) 3.61
Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A (2009) 3.47
Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron (2004) 3.38
Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron (1995) 3.37
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett (1998) 3.26
Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci (2007) 2.96
Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol (2008) 2.78
The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci (1998) 2.78
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67
Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods Enzymol (1999) 2.65
Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci (2004) 2.65
Genetic prion disease: the EUROCJD experience. Hum Genet (2005) 2.64
Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A (2004) 2.62
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A (1999) 2.51
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46
A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci (1987) 2.43
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis (2006) 2.41
In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology (2007) 2.24
Clinical phenotype of Parkinson disease dementia. Neurology (2006) 2.22
Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol (2005) 2.21
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res (1997) 2.05
Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet (2006) 2.03
Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry (2002) 1.98
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A (1996) 1.94
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. Am J Pathol (2000) 1.91
Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci (2006) 1.89
Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease. Am J Pathol (1992) 1.86
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain (2002) 1.85
Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci (2001) 1.84
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem (2004) 1.79
Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem (2002) 1.77
Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta (2009) 1.77
Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm (Vienna) (2004) 1.74
Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci (2004) 1.74
Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Virol (2001) 1.73
Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology (2005) 1.65
Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol (2000) 1.64
PrPSc accumulation in myocytes from sheep incubating natural scrapie. Nat Med (2004) 1.63
Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci (2005) 1.62
Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol (2003) 1.59
Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology (2005) 1.56
alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J (2004) 1.54
Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience (2005) 1.51
A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem (1993) 1.49
Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol (1996) 1.47
Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem (2002) 1.44
Prions in milk from ewes incubating natural scrapie. PLoS Pathog (2008) 1.43
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (2000) 1.41
Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging (2008) 1.41
Discriminating scrapie and bovine spongiform encephalopathy isolates by infrared spectroscopy of pathological prion protein. J Biol Chem (2004) 1.41
The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology (2007) 1.36
Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res (1997) 1.33
Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry (2003) 1.33
Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet (2002) 1.33
Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol (1998) 1.31